Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acer Therapeutics, NCATS to develop emetine as treatment for Covid-19
In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.
In this regard, the Texas-based Acer Therapeutics has signed a research collaboration agreement with NCATS, which is one of the National Institutes of Health (NIH) in the US.
According to jCyte, treatment with jCell is a minimally-invasive intravitreal injection, which can be carried out in an ophthalmologist’s office with topical anesthetic. The entire procedure is said
Entyvio SC will be made available in both a pre-filled syringe and a pre-filled pen. UC and CD are two of the most common forms of inflammatory bowel
Trastuzumab deruxtecan has previously received SAKIGAKE designation for this second potential indication and will receive an expedited review time of six months. Currently, there are no HER2 directed
The trial, which is planned to start imminently in multiple hospitals in Canada, will enroll approximatively 200 hospitalized COVID-19 patients for a treatment duration of 14 days. «
The Phase I trial includes both a monotherapy arm as well as a combination arm. Per protocol, the monotherapy arm began first, with the first patient dosed in
In March, the companies forged a collaboration to co-develop and supply potential mRNA-based coronavirus vaccines that include BNT162. The early-stage trial for the Covid-19 vaccine candidate is part of
“Receiving PRIME designation for sotatercept from the EMA mere weeks after the FDA granted it Breakthrough Therapy designation further strengthens our belief that sotatercept could eventually alter the
VIR-2703 is a result of the recently announced expansion of the firms’ multi-target existing collaboration for the development and commercialisation of RNAi therapeutics for infectious diseases. The partnership
CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with AML, who achieved complete remission (CR) or CR with incomplete blood count recovery